Myelodysplastic Syndromes: all 2,165 studies
Page 20 of 22. Open to participants first (322), then studies with results posted, then the rest; newest registration first within each.
- Transfusion Effects in Myelodysplastic Patients: Limiting ExposureWithdrawnNCT00202371Phase 4
- Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic PatientsCompletedNCT00195533
- Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AMLCompletedNCT00195104Phase 1/2
- Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDSCompletedNCT00195000Phase 2
- Haploidentical Stem Cell Transplantation for Patients With Hematologic MalignanciesCompletedNCT00186823Phase 3
- Non-Myeloablative Allogeneic Transplant for Myelodysplastic Syndromes and Myeloproliferative DisordersCompletedNCT00186576Not applicable
- Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic MalignanciesCompletedNCT00186342Not applicable
- TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPDCompletedNCT00185796Phase 2
- WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML)Status unknownNCT00153582Phase 2
- Stem Cell Transplantation for Patients With Hematologic MalignanciesCompletedNCT00152139Phase 3
- Creation of Bone Marrow Microenvironment for Treatment of Myelodysplastic Syndrome (MDS) in Conjunction With Allogeneic Stem Cell TransplantationWithdrawnNCT00148980Phase 2
- Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the BloodCompletedNCT00146055Phase 2
- Haploidentical Stem Cell Transplant for Treatment Refractory Hematological MalignanciesCompletedNCT00145613Phase 2
- Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell TransplantationCompletedNCT00144703Phase 2
- Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell TransplantationCompletedNCT00144677Phase 2
- Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the BloodTerminatedNCT00143884Phase 2
- Stem Cell Transplantation as Immunotherapy for Hematologic MalignanciesCompletedNCT00143559Phase 2
- A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)CompletedNCT00136461Phase 2
- Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous LeukemiaCompletedNCT00136422Phase 1
- Quality of Life of Adult Cancer Survivors Who Have Undergone a Previous Bone Marrow or Peripheral Stem Cell Transplant for a Childhood Hematologic CancerCompletedNCT00126477
- Clofarabine in Adult Patients With Advanced Solid TumorsCompletedNCT00125840Phase 1
- Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromesCompletedNCT00121303Phase 3
- Metoclopramide to Treat Anemia in Patients With Myelodysplastic Syndrome (MDS)WithdrawnNCT00120653Phase 2
- Donor Bone Marrow Transplant in Treating Young Patients With Cancer or a Non-Cancerous DiseaseCompletedNCT00118326Phase 1/2
- Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic LeukemiaTerminatedNCT00118196Phase 2
- Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative DisordersCompletedNCT00114257Phase 1
- SCIO-469: Open-Label Study for Patients With Myelodysplastic Syndromes.CompletedNCT00113893Phase 2
- Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic MalignanciesTerminatedNCT00113828Phase 2
- Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic MalignanciesTerminatedNCT00113646Phase 2
- Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00112567Phase 1/2
- MK0457 in Patients With Leukemia (0457-003)CompletedNCT00111683Phase 1
- Campath-1H + FK506 and Methylprednisolone for GVHDCompletedNCT00109993Phase 2
- Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)TerminatedNCT00109538Phase 3
- Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell TransplantCompletedNCT00107354Phase 1
- Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00104975Phase 1
- Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic SyndromesCompletedNCT00104962Phase 1
- Arsenic Trioxide and Cholecalciferol (Vitamin D) in Treating Patients With Myelodysplastic SyndromesTerminatedNCT00104806Phase 2
- Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT00101296Phase 1
- MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid LeukemiaCompletedNCT00101179Phase 1
- A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)TerminatedNCT00100152Phase 1
- SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic SyndromesCompletedNCT00098826Phase 1
- Amifostine in Treating Young Patients With Newly Diagnosed De Novo Myelodysplastic SyndromesCompletedNCT00098683Phase 2
- Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic SyndromesCompletedNCT00098423Phase 1
- Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell TransplantationCompletedNCT00096096Phase 2
- XK469R in Treating Patients With Refractory Hematologic CancerCompletedNCT00095797Phase 1
- A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic SyndromeCompletedNCT00095264Phase 2
- Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi AnemiaCompletedNCT00093743Phase 1
- Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic SyndromesCompletedNCT00093366Phase 1/2
- Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood CancersCompletedNCT00089596Phase 1/2
- Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell TransplantationCompletedNCT00089037Phase 1/2
- Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous LeukemiaCompletedNCT00087204Phase 1
- Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)CompletedNCT00086125Phase 2
- Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic CancerWithdrawnNCT00085449Phase 1/2
- CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic PhaseCompletedNCT00084916Phase 2
- Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant DiseasesStatus unknownNCT00084695Phase 2
- VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk MyelodysplasiaCompletedNCT00083187Phase 2
- Study of the Emotional Needs of Caregivers of Stem Cell Transplantation PatientsCompletedNCT00082654Not applicable
- OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic MalignanciesWithdrawnNCT00081055Phase 2
- T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic MalignanciesCompletedNCT00080925Phase 1
- Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell TransplantCompletedNCT00078858Phase 1/2
- 3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT00077558Phase 1
- Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic SyndromeCompletedNCT00077116Phase 2
- Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic SyndromesCompletedNCT00075010Phase 1/2
- Infliximab in Treating Patients With Myelodysplastic SyndromeCompletedNCT00074074Phase 2
- A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS)CompletedNCT00072969Phase 2
- VNP40101M and Cytarabine in Treating Patients With Hematologic MalignanciesCompletedNCT00070538Phase 1
- Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CMLTerminatedNCT00069992Phase 2
- Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic MalignanciesCompletedNCT00068523Not applicable
- Cholecalciferol in Treating Patients With Myelodysplastic SyndromeCompletedNCT00068276Phase 2
- Voriconazole in Preventing Fungal Infections in Children With Neutropenia After ChemotherapyCompletedNCT00066599Phase 2
- Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer TreatmentCompletedNCT00066248Phase 2
- Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic SyndromeCompletedNCT00065143Phase 2
- Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic SyndromesCompletedNCT00064974Phase 2
- Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML)CompletedNCT00064584Phase 1
- Paricalcitol in Treating Patients With Myelodysplastic SyndromeCompletedNCT00064376Phase 2
- Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell TransplantationCompletedNCT00064311Phase 1/2
- 3-AP and Cytarabine in Treating Patients With Hematologic CancerCompletedNCT00064090Phase 1
- Moxifloxacin Compared With Ciprofloxacin/Amoxicillin in Treating Fever and Neutropenia in Patients With CancerTerminatedNCT00062231Not applicable
- Total-Body Irradiation, Cyclophosphamide, and Stem Cell Transplantation in Treating Patients With Hematologic CancerCompletedNCT00062140Phase 1
- Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic AnemiasCompletedNCT00061763Phase 2
- Experimental Bone Marrow Transplant ProtocolCompletedNCT00061581Phase 2
- Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive CancerCompletedNCT00060372Phase 1
- Study of High-Dose Pulse Administration DN-101 (Calcitriol) in Patients With Myelodysplastic Syndrome (MDS)Status unknownNCT00057031Phase 2
- Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic DisordersCompletedNCT00055653Phase 2
- Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative DisorderCompletedNCT00054340Phase 1/2
- Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic AnemiaCompletedNCT00054236Phase 1
- Fludarabine/Carboplatin/Topotecan w/Thalidomide for Relapsed/Refractory AML, CML and MDSCompletedNCT00053287Phase 2
- Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic CancerCompletedNCT00053196Phase 2
- Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic AnemiaCompletedNCT00053157Not applicable
- Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic SyndromeCompletedNCT00053001Phase 2
- Doxercalciferol in Treating Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic LeukemiaCompletedNCT00052832Phase 2
- Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell TransplantTerminatedNCT00052598Phase 1/2
- Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell TransplantationCompletedNCT00052520Phase 1/2
- A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic SyndromesCompletedNCT00050843Phase 3
- Study of Tipifarnib in Patients With High-Risk Myelodysplastic Syndrome (MDS)CompletedNCT00050154Phase 2
- VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic SyndromeCompletedNCT00049686Phase 1
- Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative DisorderCompletedNCT00049634Phase 1/2
- Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid LeukemiaTerminatedNCT00049582Phase 1
- Cytogenetic Studies in Acute Leukemia and Multiple MyelomaActive, not recruitingNCT00048958
- Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic SyndromeStatus unknownNCT00047268Phase 3